Breaking News, Collaborations & Alliances

Amgen, Selexis Expand R&D License Agreement

Will evaluate the SURE CHO-M Cell Line for R&D

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen has expanded its R&D license agreement with Selexis SA to include an evaluation of Selexis’ SURE CHO-M Cell Line for R&D. Amgen will be able to evaluate the SURE CHO-M Cell Line in conjunction with the Selexis SUREtech Vectors for improved R&D.    “Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable,” said Igor Fisch, Ph.D., president and chief executive officer of Selexis. “Selex...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters